NCT06310005View on ClinicalTrials.gov

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Healthy
Interventions
DRUG

BI 3006337

BI 3006337

DRUG

Placebo

Placebo

Trial Locations (1)

160-0004

Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06310005 - A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated | Biotech Hunter | Biotech Hunter